San Francisco startup Framework Therapeutics is also working on an oral, as soon as-daily GLP-one drug called GSBR-1290—the drug surpassed Wall Street’s expectations in June any time a mid-stage examine showed typical weight loss of all-around six% and it ideas to begin another mid-phase demo toward the tip of this calendar year—that founder